Cargando…
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
BACKGROUND: RAS (KRAS and NRAS) testing is required to predict anti-epidermal growth factor receptor (EGFR) treatment efficacy in metastatic colorectal cancer (CRC). Although direct sequencing (DS) with manual microdissection (MMD) is widely used, a diagnostic kit providing rapid detections of RAS m...
Autores principales: | Yoshino, Takayuki, Muro, Kei, Yamaguchi, Kensei, Nishina, Tomohiro, Denda, Tadamichi, Kudo, Toshihiro, Okamoto, Wataru, Taniguchi, Hiroya, Akagi, Kiwamu, Kajiwara, Takeshi, Hironaka, Shuichi, Satoh, Taroh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486202/ https://www.ncbi.nlm.nih.gov/pubmed/26137573 http://dx.doi.org/10.1016/j.ebiom.2015.02.007 |
Ejemplares similares
-
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study()
por: Taniguchi, Hiroya, et al.
Publicado: (2018) -
A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2019) -
Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2020) -
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
por: Aoki, Yu, et al.
Publicado: (2023) -
Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in
RAS
wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study
por: Yuki, Satoshi, et al.
Publicado: (2023)